Right Heart Score for Predicting Outcome in Idiopathic, Familial, or Drug-and ToxinAssociated Pulmonary Arterial Hypertension ABSTRACT OBJECTIVES This study sought to determine whether a simple score combining indexes of right ventricular (RV) function and right atrial (RA) size would offer good discrimination of outcome in patients with pulmonary arterial hypertension (PAH).
BACKGROUND Identifying a simple score of outcome could simplify risk stratification of patients with PAH and potentially lead to improved tailored monitoring or therapy.
METHODS We recruited patients from both Stanford University (derivation cohort) and VU University Medical Center (validation cohort). The composite endpoint for the study was death or lung transplantation. A Cox proportional hazard with bootstrap CI adjustment model was used to determine independent correlates of death or transplantation.
A predictive score was developed using the beta coefficients of the multivariable models.
RESULTS For the derivation cohort (n ¼ 95), the majority of patients were female (79%), average age was 43 AE 11 years, mean pulmonary arterial pressure was 54 AE 14 mm Hg, and pulmonary vascular resistance index was 25 AE 12 Wood units Â m To date, only a few studies have investigated whether RA size or function has incremental value to RV function in predicting outcome in PAH. The importance of RA size in PAH was first suggested by Bustamente-Labarta et al. (7) in their series of 25 patients. In a larger study in patients with PAH (n ¼ 81), Raymond et al. (8) found that there was a trend for an independent association between RA area index (p ¼ 0.106) and the composite endpoint of death or transplantation. To our knowledge, no study has of yet also investigated the prognostic value of RA function measured by active and passive emptying fractions (RAEF) in PAH.
For our study, we first hypothesized that measures of RA size or function would be independently associated with event-free survival in PAH. We further hypothesized that a simple score combining quantitative measures of right heart size or function would provide good discrimination of outcome in PAH.
METHODS
STUDY DESIGN. Our study included a derivation cohort at Stanford University, followed by a validation cohort at the VU Medical Center. After ethics committee approval, consecutive adult patients followed at Stanford University between January 11, 1999 and January 12, 2009 with a confirmed diagnosis of idiopathic or drug and toxin PAH were considered for inclusion in the study. The diagnosis of PAH was on the basis of the standard definition of mean pulmonary arterial pressure $25 mm Hg and pulmonary artery wedge pressure #15 mm Hg (9) . We excluded patients for whom an echocardiogram was not available and patients with evidence of atrial fibrillation at baseline, left heart failure, and significant parenchymal lung disease. Patients recruited at the VU Medical Center had a diagnosis of idiopathic or familial PAH and underwent cardiac magnetic resonance (CMR) as part of a prospective study to evaluate the role of CMR in the management of PAH, for which medical ethical consent approval was obtained.
The composite endpoint of the study was death or lung transplantation. Death was verified through the national Social Security Death Index and transplantation through chart review. Data collection included demographics, 6-min walking distance (6MWD), estimated glomerular filtration rate, N-terminal pro-B-type natriuretic peptide (NTproBNP) levels, diffusion capacity of carbon monoxide, and hemodynamics. Renal function was estimated using the modified diet and renal equation (10) . For purposes of standardization, data were collected on the first outpatient visit after stabilization on disease-modifying medications (prostanoids, endothelin receptor blockers, or phosphodiesterase inhibitors). We chose this time point for 2 reasons.
First, this time point corresponded to the same day patients completed echocardiography, 6MWD, and laboratory testing (metabolic panel and NT-proBNP).
In addition, the baseline right heart catheterization was often obtained within a 3-to 6-month time frame of this visit. Haddad et al.
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RESULTS STUDY POPULATION.
Of 128 patients with idiopathic and drug-and toxin-associated PAH who were seen during the study period, 106 were enrolled in the prospective registry. Eleven patients were excluded from the study for the following reasons: unavailable
to follow-up (n ¼ 5), left heart failure (n ¼ 2), and restrictive lung disease (n ¼ 1). Table 1 , and 33%, respectively, and the revised NIH prediction scores were 91%, 71%, and 63% (17).
Several parameters of right heart structure and function were strongly related to outcome on univariate analysis ( Table 3) . The strongest relationships were found with RVEDA index, RVESA index, RVFAC, TAPSE, RA size, active RAEF, and log NT-proBNP levels. In addition, New York Heart Association (NYHA) functional class, resting SBP, kidney function, low cardiac index on right heart catheterization, and PVRI were associated with outcome. Figure 4 presents the c-statistic of the RV and RA parameters, as well as their Kaplan-Meier survival curves from RVFAC and RA index categories. With the area-length The multivariate models presented are all p < 0.001. PVRI is based on the most recent right heart catheterization. r corresponds to partial correlation coefficients.
NT-proBNP ¼ N-terminal pro-B-type natriuretic peptide; RAEF ¼ right atrial emptying fractions; RAI ¼ right atrial area index; RVFAC ¼ right ventricular fractional area change; TAPSE ¼ tricuspid annular systolic excursion; TR ¼ tricuspid regurgitation; other abbreviations as in Table 1 . ters. Although our sample size was small, confidence in our results is provided by the fact that the right heart score correlated well with established outcome scores, the findings were validated in an independent cohort, and the results were consistent using different imaging modalities. In a recent publication, in a large series of patients with PAH, Fine et al. (18) showed that RV global longitudinal strain (RVGLS), log NT-proBNP levels, and NYHA functional class were independent correlates of clinical deterioration in patients with PAH. Consistent with the study of With echocardiography, different metrics of RV systolic function have been considered, including RVFAC, TAPSE, RVMPI, and more recently RVGLS (3, 12, 13, 18) . In our study, RVFAC emerged as a stronger correlate of outcome than either TAPSE or RVMPI. In a recent study, we showed that RVFAC was more closely related to RVEF than TAPSE (19) . Moreover, we showed that an RVFAC of 25% corresponded best to an RVEF of Tables 1 and 2. function compared with RVFAC and TAPSE in PAH; ongoing studies are currently validating the findings in independent cohorts.
One of the most important contributions of our study was to prove the independent contribution to RA size (22) . In fact, in contrast to studies on atrial remodeling in left heart failure, there have been a limited number of studies addressing atrial remodeling or atrial function in PAH (7, 8, 23 ).
Bustamante-Labarta et al. Abbreviations as in Tables 1, 2 , and 4. as did the validation cohort. Second, we did not include more complex imaging modalities, such as strain imaging, in our study. Finally, it is important to emphasize that our study focused on prevalent cases of patients with PAH, rather than incident treatmentnaive patients.
CONCLUSIONS
In this study, we showed that in patients with idiopathic, familial, or drug-and toxin-associated PAH, a simple right heart score combining indexes of right heart remodeling and function could predict long- 
